B J Carter

Summary

Publications

  1. ncbi request reprint Adeno-associated virus vectors in clinical trials
    Barrie J Carter
    Targeted Genetics, Seattle, WA 98101, USA
    Hum Gene Ther 16:541-50. 2005
  2. ncbi request reprint A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease
    M L Aitken
    Department of Medicine and Pediatrics, University of Washington, Seattle, 98195, USA
    Hum Gene Ther 12:1907-16. 2001
  3. doi request reprint Effect of gene therapy on visual function in Leber's congenital amaurosis
    James W B Bainbridge
    Institute of Ophthalmology, University College London, London, United Kingdom
    N Engl J Med 358:2231-9. 2008
  4. ncbi request reprint AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice
    Robin J Ziegler
    Genzyme Corporation, 31 New York Avenue, Framingham, MA 01701 9322, USA
    Mol Ther 9:231-40. 2004
  5. ncbi request reprint A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies
    John A Wagner
    Department of Molecular Pharmacology, Stanford CCSR Building, Stanford, CA 94305 5174, USA
    Hum Gene Ther 13:1349-59. 2002
  6. pmc Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi
    Jodi L McBride
    Departments of Internal Medicine, Molecular Physiology and Biophysics, and Neurology, University of Iowa, Iowa City, IA 52242, USA
    Proc Natl Acad Sci U S A 105:5868-73. 2008
  7. ncbi request reprint Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial
    Richard B Moss
    Department of Pediatrics, Stanford University, Stanford, CA 94305, and Division of Respiratory Diseases, Children s Hospital Boston, MA 02115, USA
    Hum Gene Ther 18:726-32. 2007
  8. ncbi request reprint Workshop on long-term follow-up of participants in human gene transfer research
    Kara Nyberg
    Minneapolis, MN, USA
    Mol Ther 10:976-80. 2004
  9. ncbi request reprint Correlation between DNA transfer and cystic fibrosis airway epithelial cell correction after recombinant adeno-associated virus serotype 2 gene therapy
    Terence R Flotte
    Department of Pediatrics, University of Florida, Gainesville, 32610, USA
    Hum Gene Ther 16:921-8. 2005
  10. ncbi request reprint Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspective
    Barrie J Carter
    Targeted Genetics Corporation, Seattle, WA 98101, USA
    Mol Ther 10:981-9. 2004

Collaborators

  • Terence R Flotte
  • Beverly Davidson
  • Alexander J Smith
  • J Bainbridge
  • James Wilson
  • Guangping Gao
  • A J Thrasher
  • Richard B Moss
  • Jodi L McBride
  • Kara Nyberg
  • Robin J Ziegler
  • Robert M Frederickson
  • John A Wagner
  • M L Aitken
  • Brian L Gilmore
  • Haim Burstein
  • Patrick D Staber
  • Scott Q Harper
  • InĂ¢s Martins
  • Ryan L Boudreau
  • Alex Mas Monteys
  • Barry Polisky
  • Richard W Peluso
  • John P Clancy
  • Dana B Martin
  • Joseph Pilewski
  • Mark Pian
  • John Colombo
  • David A Waltz
  • Henry L Dorkin
  • Pamela L Zeitlin
  • Thomas Ferkol
  • Bonnie Ramsey
  • Frank Accurso
  • L Terry Spencer
  • Carlos Milla
  • Alison E Heald
  • Christine M Barbon
  • Simon Godwin
  • Maribeth Cherry
  • Daniel Rosenblum
  • Robert J Desnick
  • Donna Armentano
  • Stephen Rose
  • David W Souza
  • Richard J Gregory
  • Theresa Chen
  • Seng H Cheng
  • Scott M Lonning
  • Stephanie L Simek
  • Carolyn Wilson
  • Christine Ford
  • Samuel C Wadsworth
  • Richard Peluso
  • Cynthia Dunbar
  • Chester Li
  • Anne M Pilaro
  • Ilynn B Nepomuceno
  • William B Guggino
  • Jeffrey J Wine
  • Byron W Brown
  • Phyllis Gardner
  • Sue DiMiceli
  • Julie K Desch
  • Thomas C Reynolds
  • Anna H Messner
  • Carol K Conrad
  • Alexander M Norbash
  • Mary Lynn Moran
  • Eric P Batson
  • R B Moss
  • T C Reynolds
  • M E Dovey
  • R L Gibson
  • M R Tonelli
  • D A Waltz
  • B W Ramsey
  • S C McNamara

Detail Information

Publications12

  1. ncbi request reprint Adeno-associated virus vectors in clinical trials
    Barrie J Carter
    Targeted Genetics, Seattle, WA 98101, USA
    Hum Gene Ther 16:541-50. 2005
  2. ncbi request reprint A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease
    M L Aitken
    Department of Medicine and Pediatrics, University of Washington, Seattle, 98195, USA
    Hum Gene Ther 12:1907-16. 2001
    ..RNA-specific PCR did not detect vector-derived mRNA. This Phase I trial shows that aerosolized tgAAVCF is safe and widely delivered to the proximal airways of CF subjects by nebulization...
  3. doi request reprint Effect of gene therapy on visual function in Leber's congenital amaurosis
    James W B Bainbridge
    Institute of Ophthalmology, University College London, London, United Kingdom
    N Engl J Med 358:2231-9. 2008
    ..These findings provide support for further clinical studies of this experimental approach in other patients with mutant RPE65. (ClinicalTrials.gov number, NCT00643747 [ClinicalTrials.gov].)...
  4. ncbi request reprint AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice
    Robin J Ziegler
    Genzyme Corporation, 31 New York Avenue, Framingham, MA 01701 9322, USA
    Mol Ther 9:231-40. 2004
    ..Together, these results demonstrate that AAV2-mediated gene transfer that limits the expression of alpha-galactosidase A to the liver may be a viable strategy for treating Fabry disease...
  5. ncbi request reprint A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies
    John A Wagner
    Department of Molecular Pharmacology, Stanford CCSR Building, Stanford, CA 94305 5174, USA
    Hum Gene Ther 13:1349-59. 2002
    ..In summary, this Phase II trial confirms the safety of tgAAVCF but provides little support of its efficacy in the within-patient controlled sinus study. Various potentially confounding factors are discussed...
  6. pmc Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi
    Jodi L McBride
    Departments of Internal Medicine, Molecular Physiology and Biophysics, and Neurology, University of Iowa, Iowa City, IA 52242, USA
    Proc Natl Acad Sci U S A 105:5868-73. 2008
    ....
  7. ncbi request reprint Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial
    Richard B Moss
    Department of Pediatrics, Stanford University, Stanford, CA 94305, and Division of Respiratory Diseases, Children s Hospital Boston, MA 02115, USA
    Hum Gene Ther 18:726-32. 2007
    ..Because gene transfer is the simplest, most basic way to correct the underlying genetic defect that leads to disease in CF, further research is warranted to develop an effective gene transfer agent for the treatment of CF...
  8. ncbi request reprint Workshop on long-term follow-up of participants in human gene transfer research
    Kara Nyberg
    Minneapolis, MN, USA
    Mol Ther 10:976-80. 2004
  9. ncbi request reprint Correlation between DNA transfer and cystic fibrosis airway epithelial cell correction after recombinant adeno-associated virus serotype 2 gene therapy
    Terence R Flotte
    Department of Pediatrics, University of Florida, Gainesville, 32610, USA
    Hum Gene Ther 16:921-8. 2005
    ..The observation of sizeable physiological correction in the face of low mRNA levels may reflect the regulatory role of low levels of CFTR protein as an activator of other chloride channels...
  10. ncbi request reprint Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspective
    Barrie J Carter
    Targeted Genetics Corporation, Seattle, WA 98101, USA
    Mol Ther 10:981-9. 2004
  11. ncbi request reprint Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study
    Terence R Flotte
    Department of Pediatrics and Powell Gene Therapy Center, University of Florida, Gainesville, FL 32610 0296, USA
    Hum Gene Ther 14:1079-88. 2003
    ..These data indicate the need for continued evaluation of rAAV-CFTR vectors in additional clinical trials...
  12. ncbi request reprint Nonclinical toxicology in support of licensure of gene therapies. Arlington, VA, USA, March 13-14, 2003
    Robert M Frederickson
    TherImmune Research Corporation, Gaithersburg, MD 20879, USA
    Mol Ther 8:8-10. 2003